Ares Financial Consulting’s Abivax ABVX Stock Holding History

Ares Financial Consulting’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6	Closed	-$800	–	1070
2026 Q2	$800	Buy	+6	New	+$679	﹤0.01%	1037

Other funds holding ABVX

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Western Standard LLC Los Angeles, California $424M AUM 17.4% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Ares Financial Consulting's ABVX Position: Q3 2026 in Review

Ares Financial Consulting sold out of Abivax (ABVX) in Q3 2026, closing a stake of 6 shares — an estimated $800 sold.

Ares Financial Consulting first reported a position in ABVX in Q2 2026 and held it in 1 quarter. The position peaked at $800 in Q2 2026. 104 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

Ares Financial Consulting reported no remaining Abivax position as of Q3 2026 after selling out during the quarter.
Ares Financial Consulting sold 6 Abivax shares in Q3 2026, an estimated $800.
Ares Financial Consulting first reported a position in Abivax in Q2 2026 and held it in 1 quarter.
Ares Financial Consulting's Abivax position peaked at $800 in Q2 2026.
104 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.